Liquidia (LQDA) Share-based Compensation Growth (3y) (2022 - 2026)
Powered by 
Analysis
Liquidia (LQDA) Share-based Compensation Growth (3y) (2022 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.43 Bn | 625.67 Bn | 17.26 Bn | -83.20% |
| 2 | AbbVie | 442.46 Bn | 435.89 Bn | 12.70 Bn | -2.48% |
| 3 | Merck | 366.77 Bn | 359.63 Bn | 12.21 Bn | 20.81% |
| 4 | Novartis Ag | 266.59 Bn | 258.90 Bn | 11.24 Bn | - |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn | 18.94% |
| 6 | Sanofi | 52.40 Bn | 45.02 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn | 7.25% |
| 9 | United Therapeutics | 21.53 Bn | 18.87 Bn | 683.80 Mn | - |
| 10 | Liquidia | 6.11 Bn | 5.82 Bn | 160.92 Mn | 2.62% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.62% |
| Mar 31, 2026 | -1.05% |
| Dec 31, 2025 | 58.26% |
| Sep 30, 2025 | 0.24% |
| Jun 30, 2025 | 4.17% |
| Mar 31, 2025 | 8.59% |
| Dec 31, 2024 | 9.56% |
| Sep 30, 2024 | 17.14% |
| Jun 30, 2024 | 23.42% |
| Mar 31, 2024 | 23.74% |
| Dec 31, 2023 | 36.37% |
| Sep 30, 2023 | 106.75% |
| Jun 30, 2023 | 113.34% |
| Mar 31, 2023 | 121.21% |
| Dec 31, 2022 | -3.97% |